Personalized medicine and treatment approaches in non-small-cell lung carcinoma [0.03%]
非小细胞肺癌的个体化治疗概述
Joseph Vadakara,Hossein Borghaei
Joseph Vadakara
Chemotherapy has been the traditional backbone for the management of metastatic lung cancer. Multiple trials have shown the benefits of treatment with platinum doublets in lung cancer. This "one treatment fits all" approach was further refi...
Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent [0.03%]
μ型阿片受体(OPRM1)在阿拉伯血统的阿片类药物依赖者治疗结局中的预测作用
Laith N Al-Eitan,Saied A Jaradat,Steve Ys Su et al.
Laith N Al-Eitan et al.
Background: A number of research studies on the genetics of opiate dependence have focused on the μ-opioid receptor (OPRM1), which is a primary target for opiates. This study aims to identify genetic polymorphisms within...
Geetha Ramachandran,Soumya Swaminathan
Geetha Ramachandran
Background: Tuberculosis is one of the major public health problems worldwide. Modern antituberculous treatment can cure most patients; cure rates > 95% are achieved with standard short-course chemotherapy regimens contai...
Pascal H Vuilleumier,Ulrike M Stamer,Ruth Landau
Pascal H Vuilleumier
Translating pharmacogenetics to clinical practice has been particularly challenging in the context of pain, due to the complexity of this multifaceted phenotype and the overall subjective nature of pain perception and response to analgesia....
Individualized immunosuppression in transplant patients: potential role of pharmacogenetics [0.03%]
药理基因组学在移植患者个体化免疫抑制中的潜在作用
Hamid Abboudi,Iain Am Macphee
Hamid Abboudi
The immunosuppressive drugs used to prevent the rejection of transplanted organs have a narrow therapeutic index. Under treatment results in episodes of rejection leading to either damage or loss of the organ. Over immunosuppression increas...
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics [0.03%]
阿片受体和多巴胺转运体基因在美沙酮维持治疗中的药理遗传学意义研究
Daniel T Barratt,Janet K Coller,Richard Hallinan et al.
Daniel T Barratt et al.
Background: Genetic variability in ABCB1, encoding the P-glycoprotein efflux transporter, has been linked to altered methadone maintenance treatment dose requirements. However, subsequent studies have indicated that addit...
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions [0.03%]
遗传学在子痫前期的作用及潜在的药理遗传学干预措施
Paula Juliet Williams,Linda Morgan
Paula Juliet Williams
The pregnancy-specific condition pre-eclampsia not only affects the health of mother and baby during pregnancy but also has long-term consequences, increasing the chances of cardiovascular disease in later life. It is accepted that pre-ecla...
Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy [0.03%]
血清素转运体基因启动子区多态性与精神障碍的关系：病理和药物治疗的回顾分析
George A Kenna,Nick Roder-Hanna,Lorenzo Leggio et al.
George A Kenna et al.
Serotonin (5-HT) regulates important biological and psychological processes including mood, and may be associated with the development of several psychiatric disorders. An association between psychopathology and genes that regulate 5-HT neu...
Rebecca Pavlos,Elizabeth J Phillips
Rebecca Pavlos
Antiretroviral therapy (ART) has evolved considerably over the last three decades. From the early days of monotherapy with high toxicities and pill burdens, through to larger pill burdens and more potent combination therapies, and finally, ...
Role of cytochrome P450 genotype in the steps toward personalized drug therapy [0.03%]
细胞色素P450基因型在向个性化药物治疗的过程中所起的作用
Larisa H Cavallari,Hyunyoung Jeong,Adam Bress
Larisa H Cavallari
Genetic polymorphism for cytochrome 450 (P450) enzymes leads to interindividual variability in the plasma concentrations of many drugs. In some cases, P450 genotype results in decreased enzyme activity and an increased risk for adverse drug...